Kim, D.; Jang, G.; Hwang, J.; Wei, X.; Kim, H.; Son, J.; Rhee, S.-J.; Yun, K.-H.; Oh, S.-K.; Oh, C.-M.;
et al. Combined Therapy of Low-Dose Angiotensin Receptor–Neprilysin Inhibitor and Sodium–Glucose Cotransporter-2 Inhibitor Prevents Doxorubicin-Induced Cardiac Dysfunction in Rodent Model with Minimal Adverse Effects. Pharmaceutics 2022, 14, 2629.
https://doi.org/10.3390/pharmaceutics14122629
AMA Style
Kim D, Jang G, Hwang J, Wei X, Kim H, Son J, Rhee S-J, Yun K-H, Oh S-K, Oh C-M,
et al. Combined Therapy of Low-Dose Angiotensin Receptor–Neprilysin Inhibitor and Sodium–Glucose Cotransporter-2 Inhibitor Prevents Doxorubicin-Induced Cardiac Dysfunction in Rodent Model with Minimal Adverse Effects. Pharmaceutics. 2022; 14(12):2629.
https://doi.org/10.3390/pharmaceutics14122629
Chicago/Turabian Style
Kim, Donghyun, Gyuho Jang, Jaetaek Hwang, Xiaofan Wei, Hyunsoo Kim, Jinbae Son, Sang-Jae Rhee, Kyeong-Ho Yun, Seok-Kyu Oh, Chang-Myung Oh,
and et al. 2022. "Combined Therapy of Low-Dose Angiotensin Receptor–Neprilysin Inhibitor and Sodium–Glucose Cotransporter-2 Inhibitor Prevents Doxorubicin-Induced Cardiac Dysfunction in Rodent Model with Minimal Adverse Effects" Pharmaceutics 14, no. 12: 2629.
https://doi.org/10.3390/pharmaceutics14122629
APA Style
Kim, D., Jang, G., Hwang, J., Wei, X., Kim, H., Son, J., Rhee, S.-J., Yun, K.-H., Oh, S.-K., Oh, C.-M., & Park, R.
(2022). Combined Therapy of Low-Dose Angiotensin Receptor–Neprilysin Inhibitor and Sodium–Glucose Cotransporter-2 Inhibitor Prevents Doxorubicin-Induced Cardiac Dysfunction in Rodent Model with Minimal Adverse Effects. Pharmaceutics, 14(12), 2629.
https://doi.org/10.3390/pharmaceutics14122629
